Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Phase 3CompletedDevelopment Stage
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Jul 1, 2009 → Nov 1, 2010
About Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) is a phase 3 stage product being developed by Baxter for Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses. The current trial status is completed. This product is registered under clinical trial identifier NCT00892957. Target conditions include Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses.
What happened to similar drugs?
1 of 2 similar drugs in Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00892957 | Phase 3 | Completed |
| NCT00681824 | Phase 2 | Completed |
Competing Products
4 competing products in Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Epoetin alfa + Standard of Care | Johnson & Johnson | Approved | 35 |
| FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time | Baxter | Phase 2 | 32 |
| TISSEEL Lyo | Baxter | Phase 3 | 37 |
| Human thrombin + Bovine thrombin | Grifols | Phase 2 | 32 |